Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency. 1992

M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
Department of Pharmacology, Hamamatsu University School of Medicine, Japan.

The pharmacokinetics of temocapril hydrochloride, a novel prodrug-type angiotensin-I converting enzyme (ACE) inhibitor, has been studied in patients with mild (Group II) to severe (Group III) renal insufficiency in comparison with subjects with normal renal function (Group I). The pharmacokinetic parameters of the active diacid metabolite, including Cmax, AUC and half-life (t1/2), showed only slight changes between the three groups: AUC (0-inaffinity) was significantly larger in Group III than Group I, and t1/2 tended to be prolonged in Group III, but the change was not significant. The urinary recovery of the diacid was significantly decreased in Group III. (Group I, 28.1%, Group II, 21.6%, Group III, 12.8%). Compared with other ACE inhibitors, which are mainly excreted through the kidney, the plasma concentration of the active diacid metabolite was hardly influenced by renal function. It was speculated that lowering of the dose of temocapril might be recommended only in patients with severe renal insufficiency.

UI MeSH Term Description Entries
D008297 Male Males
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D013841 Thiazepines Compounds that are derivatives of THIEPINS, with a nitrogen replacing a carbon in the seven-membered heterocyclic compound. Thiazepine
D051437 Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. Kidney Insufficiency,Kidney Failure,Renal Failure,Failure, Kidney,Failure, Renal,Failures, Kidney,Failures, Renal,Insufficiency, Kidney,Kidney Failures,Kidney Insufficiencies,Renal Failures,Renal Insufficiencies

Related Publications

M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
February 2000, Japanese journal of cancer research : Gann,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
March 1989, American heart journal,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
April 1992, Annals of internal medicine,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
April 1992, Annals of internal medicine,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
January 1993, Biopharmaceutics & drug disposition,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
January 1988, Archives internationales de pharmacodynamie et de therapie,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
September 2000, European journal of pharmacology,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
April 1996, The New England journal of medicine,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
February 1997, The Journal of urology,
M Nakashima, and J Yamamoto, and M Shibata, and T Uematsu, and H Shinjo, and T Akahori, and H Shioya, and K Sugiyama, and Y Kawahara
June 1998, Ugeskrift for laeger,
Copied contents to your clipboard!